Biochemical/metabolic changes associated with hepatocellular carcinoma development in mice

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5459-5466

  El Ashmawy, Nahla E ^a   El Bahrawy, Hoda A ^a   Shamloula, Maha M ^b   El Feky, Ola A ^a  

^a Tanta University   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

Author keywords

Aldolase; E cadherin; G6PDH; Hepatocellular carcinoma; IGF 1; p53

Indexed keywords

CITRATE SYNTHASE; DIETHYLNITROSAMINE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PROTEIN P53; SOMATOMEDIN C; THIOACETAMIDE; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER WEIGHT; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; WEIGHT REDUCTION;

ANIMALS; CADHERINS; CARCINOMA, HEPATOCELLULAR; FRUCTOSE-BISPHOSPHATE ALDOLASE; GENES, P53; GLUCOSEPHOSPHATE DEHYDROGENASE; INSULIN-LIKE GROWTH FACTOR I; LIVER; LIVER NEOPLASMS; MALE; MICE; NF-KAPPA B;

EID: 84904764170     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1714-6     Document Type: Article

References (45)

1. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(4):763-8. (Pubitemid 46650579)
2. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;25(27):3787-800. (Pubitemid 43980474)
3. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB. 2005;7(1):26-34. (Pubitemid 40425754)
4. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signaling controls metabolic demand. Curr Opin Cell Biol. 2007;19(2):223-9. (Pubitemid 46386401)
5. Clemmons DR. Insulin-like growth factor-1 and its binding proteins. In: De Groot LJ, Jenmeson JL, Burger HG, editors. Endocrinology. 4th ed. Philadelphia: WB Saunders Company; 2001. p. 439-60.
6. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, Ben-Ze 'ev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol. 2003;163(4):847-57. (Pubitemid 37517891)
7. Cornellà H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res. 2011;35(5):821-5.
8. Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg. 2008;134(4):370-9. (Pubitemid 351581084)
9. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11-20.
10. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology andmolecular carcinogenesis. Gastroenterology. 2007;132(7):2557-76. (Pubitemid 46890874)
11. El-Zayadi AR, Badran HM, Shawky S, Emara S, El-Bareedy A, Sobhi M. Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. Hepatol Int. 2010;4(2):500-6.
12. Fleury P, Eberhard R. Determination of proteins by photometric, biuret method according to the technique of Gornall. Ann Biol Clin. 1951;9(10-12):453-66.
13. FrederiksWM, Vizan P, Bosch KS, Vreeling-Sindelárová H, Boren J, Cascante M. Elevated activity of the oxidative and non-oxidative pentose phosphate pathway in (pre)neoplastic lesions in rat liver. Int J Exp Pathol. 2008;89(4):232-40. (Pubitemid 352019178)
14. García-Fernández M, Castilla-Cortázar I, Díaz-Sanchez M, Navarro I, Puche JE, Castilla A, et al. Antioxidant effects of insulin-like growth factor-1 (IGF-1) in rats with advanced liver cirrhosis. BMC Gastroenterol. 2005;5(7):1-8.
15. Gebhardt SE, Thomas RG. Nutritive value of foods.U.S. Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory, Beltsville, Maryland. Home Gard Bull. 2002;72:45-62.
16. Ibrahim AS, Attia HA, Rabea AM, El-Gayar AM. Serum levels of glycosaminoglycans (GAGs) and insulin like growth factor-1 (IGF-1) as diagnostic markers for early hepatocellular carcinoma in cirrhotic patients with or without diabetes. J Med Lab Diagn. 2013;4(1):8-20.
17. Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012;1825(1):111-6.
18. Israël M and Schwartz L. The metabolic advantage of tumor cells. Mol Cancer. 2011;10(70): doi: 10.1186/1476-4598-10-70
19. Jadali F, Sayadpour D, Rakhshan M, Karimi A, Rouzrokh M, Shamsian BS, et al. Immunohistochemical detection of p53 protein expression as a prognostic factor inWilms tumor. Iran J Kidney Dis. 2011;5(3):149-53.
20. Kaufman RJ, Scheuner D, SchroderM, Shen X, Lee K, Liu CY, et al. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol. 2002;3(6):411-21. (Pubitemid 34685699)
21. Kuo WY, Lin JY, Tang TK. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer. 2000;85(6):857-64. (Pubitemid 30131478)
22. Kushida M, Kamendulis LM, Peat TJ, Klaunig JE. Dose-related induction of hepatic preneoplastic lesions by diethylnitrosamine in C57BL/6 mice. Toxicol Pathol. 2011;39(5):776-86.
23. Lou H, Kaplowitz N. Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappaB activity via IkappaB kinase-dependent and -independent mechanisms. J Biol Chem. 2007;282(40):29470-81. (Pubitemid 350043388)
24. Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, et al. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst. 2001;93(17):1330-6. (Pubitemid 32910574)
25. Massague J. TGFbeta in Cancer. Cell. 2008;134(2):215-30.
26. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 2002;95(12):2539-45. (Pubitemid 35424040)
27. Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses. 2009;1(3):852-72.
28. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002;12(1):53-9. (Pubitemid 34094990)
29. Milde-LangoschK, Hagen M, Bamberger AM, Löning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol. 2003;22(2):168-74.
30. Morgunov I, Srere PA. Interaction between citrate synthase and malate dehydrogenase: substrate channeling of oxaloacetate. J Biol Chem. 1998;273(45):29540-4. (Pubitemid 28509961)
31. Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, et al. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2010;19(2):484-91.
32. Novosyadlyy R, Dargel R, Scharf JG. Expression of insulin-like growth factor-I and insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats. Growth Horm IGF Res. 2005;15:313-23. (Pubitemid 41403766)
33. Otsuka M, Kato N, Taniguchi H, Yoshida H, Goto T, Shiratori Y, et al. Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression. Virology. 2002;296(1):84-93.
34. Paiva C, Oshima CT, Lanzoni VP, Forones NM. Apoptosis, PCNA and p53 in hepatocellular carcinoma. Hepatogastroenterology. 2002;49(46):1058-61. (Pubitemid 34809786)
35. Pinto PV, Kaplan A, Van Dreal PA. Aldolase. II. Spectrophotometric determination using an ultraviolet procedure. Clin Chem. 1969;15(5):349-60.
36. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzoglou M, et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β. Genes Dev. 2004;18(3):261-77. (Pubitemid 38199252)
37. Roncalli M, Terracciano L, Di Tommaso L, David E, Colombo M. Liver precancerous lesions and hepatocellular carcinoma: the histology report. Dig Liver Dis. 2011;43(4):S361-72.
38. Schlichtholz B, Turyn J, Goyke E, Biernacki M, Jaskiewicz K, Sledzinski Z, et al. Enhanced citrate synthase activity in human pancreatic cancer. Pancreas. 2005;30(2):99-l04.
39. Sharma S, Lakshmi KS, Chitra V, Lakshmi AI, Pharm M. Anticarcinogenic activity of allylmercaptocaptopril against aflatoxin-B1 induced liver carcinoma in rats. Eur J Gen Med. 2011;8(1):46-52.
40. Shen Y, Hirsch DS, Sasiela CA,WuWJ. Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathway. J Biol Chem. 2008;283(8):5127-37.
41. SoyamaA, Eguchi S, TakatsukiM, Kawashita Y,HidakaM, Tokai H, et al. Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology. 2008;55(85):1390-3.
42. Takeuchi H, Nakamoto T, Mori Y, Kawakami M, Mabuchi H, Ohishi Y, et al. Comparative effects of dietary fat types on hepatic enzyme activities related to the synthesis and oxidation of fatty acid and to lipogenesis in rats. Biosci Biotechnol Biochem. 2001;65(8):1748-54. (Pubitemid 33617779)
43. Tian WN, Pignatare JN, Stanton RC. Signal transduction proteins that associate with the platelet-derived growth factor (PDGF) receptor mediate the PDGF-induced release of glucose-6-phosphate dehydrogenase from permeabilized cells. J Biol Chem. 1994;269(20):14798-805. (Pubitemid 24194048)
44. Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 1996;264:484-509.
45. Wu J and Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 2011;4(30): doi: 10.1186/1756-8722-4- 30